AZA+Lus VS AZA Monotherapy in HR-MDS
ConditionHigher-risk Myelodysplastic Syndrome
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking Union Medical College Hospital
About this trial
This study is a randomized, prospective, single-center, open-label cohort study involving untreated HR-MDS patients. The patients were divided randomized into AZA+Lus cohort and AZA monotherapy cohort.
Eligibility criteria
Qualifiers
Age ≥18 years old
Diagnosed as higher-risk MDS (IPSS intermediate-2/high-risk, or IPSS-R >3.5, or IPSS-M moderate high-, high-, very high-risk)
Untreated patients
Liver and kidney function less than 2 times of upper limit of normal
Disqualifiers
With active infection
Other malignant tumors
Obvious abnormal liver and kidney function, or abnormal function of other organs
Combined with myelofibrosis
Trial design
Treatments tested in this trial
- Azacitidine (AZA)
- Luspatercept
Treatment groups
86 Participants
are divided into 2 treatment groupsLocations
This trial has no locations
Sponsors and collaborators
Peking Union Medical College Hospital
Lead sponsor
Source ClinicalTrials.gov